Search

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

Biosimilars

Innovation in Immunology | Human Health | Boehringer Ingelheim US

BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.

FDA Approves OFEV® (nintedanib) to Treat IPF | BI US

Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

Human Health Products

Click here to read more on Boehringer Ingelheim's commitment to providing innovative prescription medication to a wide range of patients and their families.

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

Biostatistics & Data Science

Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Translational Medicine & Clinical Pharmacology

We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Patient information

Patient-centric cardio-renal-metabolic disease research at Boehringer Ingelheim

COPD_Patient_brochure.pdf

Boehringer Cares Patient Assistance Program Application - Spanish

Boehringer Cares Patient Assistance Program Application - English

New agreement with Quallent expands biosimilar access

Boehringer Ingelheim enters private label agreement for biosimilar

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

PI Update for Pradaxa® (dabigatran etexilate) | BI US

Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers